Bristol Myers Squibb Company $BMY Shares Purchased by Kentucky Retirement Systems

Kentucky Retirement Systems grew its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 6.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 135,941 shares of the biopharmaceutical company’s stock after purchasing an additional 7,988 shares during the quarter. Kentucky Retirement Systems’ holdings in Bristol Myers Squibb were worth $8,245,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Swiss RE Ltd. acquired a new position in Bristol Myers Squibb during the fourth quarter worth about $25,000. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb in the second quarter worth about $25,000. Physician Wealth Advisors Inc. lifted its holdings in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares during the last quarter. Bayban bought a new position in shares of Bristol Myers Squibb during the 4th quarter valued at about $31,000. Finally, EQ Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb during the 4th quarter valued at about $32,000. Institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BMY. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday. Guggenheim restated a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Cantor Fitzgerald restated a “neutral” rating and issued a $54.00 price target on shares of Bristol Myers Squibb in a research report on Monday, July 6th. Bank of America dropped their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a report on Friday, July 10th. Finally, Weiss Ratings downgraded Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, July 16th. Eight analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $61.25.

Bristol Myers Squibb Price Performance

NYSE BMY opened at $63.24 on Thursday. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $64.96. The company has a market cap of $129.14 billion, a PE ratio of 17.76, a PEG ratio of 0.18 and a beta of 0.23. The stock’s 50-day moving average price is $57.79 and its two-hundred day moving average price is $58.22.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the company posted $1.80 earnings per share. On average, analysts predict that Bristol Myers Squibb Company will post 6.34 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.